NCT02395627 2020-07-07
Reversing Therapy Resistance With Epigenetic-Immune Modification
University of California, San Francisco
Phase 2 Terminated
University of California, San Francisco
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
H. Lee Moffitt Cancer Center and Research Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins